Page last updated: 2024-09-04

frenolicin b and pd168393

frenolicin b has been researched along with pd168393 in 1 studies

Compound Research Comparison

Studies
(frenolicin b)
Trials
(frenolicin b)
Recent Studies (post-2010)
(frenolicin b)
Studies
(pd168393)
Trials
(pd168393)
Recent Studies (post-2010) (pd168393)
180961033

Protein Interaction Comparison

ProteinTaxonomyfrenolicin b (IC50)pd168393 (IC50)
Proto-oncogene tyrosine-protein kinase SrcGallus gallus (chicken)1.0702
Epidermal growth factor receptorHomo sapiens (human)0.0143
Receptor tyrosine-protein kinase erbB-2Homo sapiens (human)0.0334
Tyrosine-protein kinase FynHomo sapiens (human)0.1543
Proto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)0.073
Receptor tyrosine-protein kinase erbB-3Homo sapiens (human)0.0011
Tyrosine-protein kinase BlkHomo sapiens (human)5.47
Cytoplasmic tyrosine-protein kinase BMXHomo sapiens (human)0.5757
Tyrosine-protein kinase JAK3Homo sapiens (human)3.14
Tyrosine-protein kinase BTKHomo sapiens (human)5.83
Receptor tyrosine-protein kinase erbB-4Homo sapiens (human)0.0047

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Barf, T; Kaptein, A1

Reviews

1 review(s) available for frenolicin b and pd168393

ArticleYear
Irreversible protein kinase inhibitors: balancing the benefits and risks.
    Journal of medicinal chemistry, 2012, Jul-26, Volume: 55, Issue:14

    Topics: Animals; Cell Line; Humans; Protein Kinase Inhibitors; Protein Kinases; Risk; Structure-Activity Relationship; Time Factors

2012